Factors associated with receipt of COVID-19 vaccination and SARS-CoV-2 seropositivity among healthcare workers in Albania (February 2021-June 2022): secondary analysis of a prospective cohort study.
COVID-19
Health care workers
Risk
SARS-CoV-2
Seropositivity
Vaccination
Journal
The Lancet regional health. Europe
ISSN: 2666-7762
Titre abrégé: Lancet Reg Health Eur
Pays: England
ID NLM: 101777707
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
12
10
2022
revised:
23
12
2022
accepted:
03
01
2023
medline:
5
4
2023
entrez:
4
4
2023
pubmed:
5
4
2023
Statut:
ppublish
Résumé
Healthcare workers (HCWs) have been disproportionally affected by COVID-19. We investigated factors associated with two- and three-dose COVID-19 vaccine uptake and SARS-CoV-2 seropositivity among 1504 HCWs enrolled (19 February-7 May 2021) in a prospective COVID-19 vaccine effectiveness cohort in Albania through a secondary analysis. We collected sociodemographic, occupational, health, prior SARS-CoV-2 infection, and COVID-19 vaccination data from all HCWs at enrollment. Vaccination status was assessed weekly through June 2022. A serum sample was collected from all participants at enrollment and tested for anti-spike SARS-CoV-2 antibodies. We analyzed HCWs characteristics and outcomes using multivariable logistic regression. By 11 June 2022, 1337 (88.9%) HCWs had received two COVID-19 vaccine doses, of whom 255 (19.1%) received a booster. Factors significantly associated with receiving three doses (adjusted odds ratio (aOR), 95% CIs) were being ≥35 years (35-44 years: 1.76 (1.05-2.97); 45-54 years: 3.11 (1.92-5.05); ≥55 years: 3.38 (2.04-5.59)) and vaccinated against influenza (1.78; 1.20-2.64). Booster dose receipt was lower among females (0.58; 0.41-0.81), previously infected (0.67; 0.48-0.93), nurses and midwives (0.31; 0.22-0.45), and support staff (0.19; 0.11-0.32). Overall 1076 (72%) were SARS-CoV-2 seropositive at enrollment. Nurses and midwifes (1.45; 1.05-2.02), support staff (1.57; 1.03-2.41), and HCWs performing aerosol-generating procedures (AGPs) (1.40; 1.01-1.94) had higher odds of being seropositive, while smokers had reduced odds (0.55; 0.40-0.75). In a large cohort of Albanian HCWs, COVID-19 vaccine booster dose uptake was very low, particularly among younger, female, and non-physician HCWs, despite evidence demonstrating the added benefit of boosters in preventing infection and severe disease. Reasons behind these disparities should be explored to develop targeted strategies in order to promote uptake in this critical population. SARS-CoV-2 seroprevalence was higher among non-physicians and HCWs performing APGs. A better understanding of the factors contributing to these differences is needed to inform interventions that could reduce infections in the future. This study was funded by the Task Force for Global Health (US Centers for Disease Control (CDC) cooperative agreement # NU51IP000873) and the World Health Organization, Regional Office for Europe
Sections du résumé
Background
UNASSIGNED
Healthcare workers (HCWs) have been disproportionally affected by COVID-19. We investigated factors associated with two- and three-dose COVID-19 vaccine uptake and SARS-CoV-2 seropositivity among 1504 HCWs enrolled (19 February-7 May 2021) in a prospective COVID-19 vaccine effectiveness cohort in Albania through a secondary analysis.
Methods
UNASSIGNED
We collected sociodemographic, occupational, health, prior SARS-CoV-2 infection, and COVID-19 vaccination data from all HCWs at enrollment. Vaccination status was assessed weekly through June 2022. A serum sample was collected from all participants at enrollment and tested for anti-spike SARS-CoV-2 antibodies. We analyzed HCWs characteristics and outcomes using multivariable logistic regression.
Findings
UNASSIGNED
By 11 June 2022, 1337 (88.9%) HCWs had received two COVID-19 vaccine doses, of whom 255 (19.1%) received a booster. Factors significantly associated with receiving three doses (adjusted odds ratio (aOR), 95% CIs) were being ≥35 years (35-44 years: 1.76 (1.05-2.97); 45-54 years: 3.11 (1.92-5.05); ≥55 years: 3.38 (2.04-5.59)) and vaccinated against influenza (1.78; 1.20-2.64). Booster dose receipt was lower among females (0.58; 0.41-0.81), previously infected (0.67; 0.48-0.93), nurses and midwives (0.31; 0.22-0.45), and support staff (0.19; 0.11-0.32). Overall 1076 (72%) were SARS-CoV-2 seropositive at enrollment. Nurses and midwifes (1.45; 1.05-2.02), support staff (1.57; 1.03-2.41), and HCWs performing aerosol-generating procedures (AGPs) (1.40; 1.01-1.94) had higher odds of being seropositive, while smokers had reduced odds (0.55; 0.40-0.75).
Interpretation
UNASSIGNED
In a large cohort of Albanian HCWs, COVID-19 vaccine booster dose uptake was very low, particularly among younger, female, and non-physician HCWs, despite evidence demonstrating the added benefit of boosters in preventing infection and severe disease. Reasons behind these disparities should be explored to develop targeted strategies in order to promote uptake in this critical population. SARS-CoV-2 seroprevalence was higher among non-physicians and HCWs performing APGs. A better understanding of the factors contributing to these differences is needed to inform interventions that could reduce infections in the future.
Funding
UNASSIGNED
This study was funded by the Task Force for Global Health (US Centers for Disease Control (CDC) cooperative agreement # NU51IP000873) and the World Health Organization, Regional Office for Europe
Identifiants
pubmed: 37013112
doi: 10.1016/j.lanepe.2023.100584
pii: S2666-7762(23)00002-9
pmc: PMC9969343
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100584Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Organisme : NCIRD CDC HHS
ID : U38 IP000873
Pays : United States
Informations de copyright
© 2023 World Health Organization.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to declare that are relevant to the content of this article.
Références
Am J Epidemiol. 2022 Jul 23;191(8):1383-1395
pubmed: 35051292
BMJ Open. 2021 Feb 22;11(2):e047216
pubmed: 33619203
Ann Intern Med. 2022 Jan;175(1):W8-W9
pubmed: 34781714
BMJ. 2021 Feb 19;372:n509
pubmed: 33608302
J Perinatol. 2021 Oct;41(10):2549-2551
pubmed: 34497336
Influenza Other Respir Viruses. 2022 Jul;16(4):626-631
pubmed: 35318799
BMJ Open. 2022 Mar 23;12(3):e057741
pubmed: 35321895
JAMA Netw Open. 2021 Dec 1;4(12):e2137257
pubmed: 34905008
J Intern Med. 2023 Jan;293(1):63-81
pubmed: 35996938
Am J Infect Control. 2021 Dec;49(12):1554-1557
pubmed: 34802705
J Hosp Infect. 2021 Feb;108:120-134
pubmed: 33212126
Vaccine. 2010 Oct 18;28(44):7207-14
pubmed: 20804802
Lancet. 2022 Apr 16;399(10334):1513-1536
pubmed: 35279232
Expert Rev Vaccines. 2021 Dec;20(12):1619-1628
pubmed: 34592123
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Postgrad Med J. 2023 Jun 15;99(1172):520-528
pubmed: 37319159
Vaccine. 2022 Apr 26;40(19):2749-2754
pubmed: 35361500
MMWR Morb Mortal Wkly Rep. 2022 Apr 15;71(15):549-555
pubmed: 35421077
Am J Epidemiol. 2021 Jan 4;190(1):161-175
pubmed: 32870978
Nat Commun. 2020 Jul 6;11(1):3436
pubmed: 32632160
Occup Environ Med. 2020 Dec 9;:
pubmed: 33298533
Nat Commun. 2021 Feb 10;12(1):905
pubmed: 33568663
Vaccine. 2019 Aug 14;37(35):5089-5095
pubmed: 31288998
Infect Control Hosp Epidemiol. 2022 Oct;43(10):1433-1438
pubmed: 34551833
Am J Infect Control. 2021 Oct;49(10):1295-1304
pubmed: 34273461
PLoS Med. 2022 May 26;19(5):e1004015
pubmed: 35617423
J Community Health. 2021 Dec;46(6):1244-1251
pubmed: 33877534
Acta Microbiol Immunol Hung. 2022 Feb 14;:
pubmed: 35156939
JAMA Netw Open. 2021 Jul 1;4(7):e2115699
pubmed: 34228126
Vaccines (Basel). 2022 Jul 27;10(8):
pubmed: 36016084
Rev Med Virol. 2021 Sep;31(5):1-16
pubmed: 33387448
N Engl J Med. 2022 May 19;386(20):1910-1921
pubmed: 35320659
BMC Pregnancy Childbirth. 2022 Jan 14;22(1):33
pubmed: 35030996
Vaccines (Basel). 2022 Jan 12;10(1):
pubmed: 35062771
N Engl J Med. 2022 May 12;386(19):1804-1816
pubmed: 35263534
Public Health. 2022 Feb;203:97-99
pubmed: 35038631
N Engl J Med. 2022 Jul 7;387(1):21-34
pubmed: 35704396
BMC Public Health. 2022 Sep 2;22(1):1667
pubmed: 36056325
BMC Immunol. 2014 Feb 06;15:5
pubmed: 24502245
Intern Emerg Med. 2022 Sep;17(6):1617-1630
pubmed: 35419722
Lancet Public Health. 2020 Sep;5(9):e475-e483
pubmed: 32745512
Nicotine Tob Res. 2023 Jan 5;25(2):177-184
pubmed: 35363877
CMAJ. 2021 Apr 19;193(16):E540-E548
pubmed: 33741725
Clin Microbiol Infect. 2021 Sep;27(9):1242-1249
pubmed: 34116205
Clin Microbiol Infect. 2021 Mar;27(3):331-340
pubmed: 33228974
Vaccines (Basel). 2022 Feb 16;10(2):
pubmed: 35214761
N Engl J Med. 2022 Jun 9;386(23):2201-2212
pubmed: 35613036
Lancet Infect Dis. 2022 Jun;22(6):781-790
pubmed: 35366962